The estimated Net Worth of Michael S Ostrach is at least $2.87 Million dollars as of 22 February 2020. Mr Ostrach owns over 8,500 units of Dynavax Technologies stock worth over $1,768,555 and over the last 18 years he sold DVAX stock worth over $378,989. In addition, he makes $721,353 as Advisor at Dynavax Technologies.
Mr has made over 7 trades of the Dynavax Technologies stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 8,500 units of DVAX stock worth $92,735 on 22 February 2020.
The largest trade he's ever made was exercising 60,780 units of Dynavax Technologies stock on 1 May 2012 worth over $57,133. On average, Mr trades about 6,273 units every 95 days since 2006. As of 22 February 2020 he still owns at least 162,104 units of Dynavax Technologies stock.
You can see the complete history of Mr Ostrach stock trades at the bottom of the page.
Michael S. Ostrach is the Advisor at Dynavax Technologies.
As the Advisor of Dynavax Technologies, the total compensation of Mr Ostrach at Dynavax Technologies is $721,353. There are 3 executives at Dynavax Technologies getting paid more, with Ryan Spencer having the highest compensation of $859,990.
Mr Ostrach is 69, he's been the Advisor of Dynavax Technologies since . There are no older and 5 younger executives at Dynavax Technologies.
Michael's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2100 POWELL STREET, SUITE 900, EMERYVILLE, CA, 94608.
Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog..., and James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Dynavax Technologies executives and other stock owners filed with the SEC include: